Targeting TMEM16A-encoded Ca<sup>2+</sup>-activated Cl<sup>-</sup> channels: a new paradigm for antihypertensive therapy?
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34294205.
- Also identified by DOI 10.1016/j.kint.2021.04.040 and PMC identifier 8500664.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hypertension is the leading risk factor for the development of heart diseases and stroke. Many hypertensive patients experience undesirable side effects to conventional antihypertensive pharmacotherapy. Cil et al. documented the antihypertensive profile of a novel molecule, TM<sub>inh</sub>-23 (2-bromodifluoroacetylamino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide), in the spontaneously hypertensive rat model of systemic hypertension. They showed that this agent reduces blood pressure by inhibiting transmembrane member 16A-encoded calcium-activated chloride channels in vascular myocytes from resistance arteries. If validated, TM<sub>inh</sub>-23 could become a useful clinical tool.
Medical subject headings
- Antihypertensive Agents
- Chloride Channels